Showing 1 – 4 of 4
Relevance | Newest | Oldest |
  • JAMA Original Investigation
    April 6, 2024

    Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial

    Richard M.听Martin,聽BM, BS, PhD; Emma L.听Turner,聽PhD; Grace J.听Young,聽MSc; Chris聽Metcalfe,聽PhD; Eleanor I.听Walsh,聽MSc; J. Athene聽Lane,聽PhD; Jonathan A. C.听Sterne,聽PhD; Sian聽Noble,聽PhD; Peter聽Holding,聽MSc; Yoav聽Ben-Shlomo,聽MBBS, PhD; Naomi J.听Williams,聽PhD; Nora聽Pashayan,聽MD, PhD; Mai Ngoc聽Bui,聽PhD; Peter C.听Albertsen,聽MD; Tyler M.听Seibert,聽MD, PhD; Anthony L.听Zietman,聽MD; Jon聽Oxley,聽MD; Jan聽Adolfsson,聽MD; Malcolm D.听Mason,聽MD; George聽Davey Smith,聽DSc; David E.听Neal,聽MD; Freddie C.听Hamdy,聽MD; Jenny L.听Donovan,聽PhD; CAP Trial Group
    Abstract Full Text
    is active quiz has multimedia
    JAMA. 2024; 331(17):1460-1470. 10.1001/jama.2024.4011

    This secondary analysis of a randomized clinical trial assesses whether screening for prostate-specific antigen reduces prostate cancer mortality at 15-year follow-up.

  • 榴莲视频 Network Open Original Investigation Imaging
    August 7, 2019

    Comparison of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy With Systematic Biopsy Alone for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis

    Martha M. C.听Elwenspoek,聽PhD; Athena L.听Sheppard,聽MSc; Matthew D. F.听McInnes,聽MD, PhD; Samuel W. D.听Merriel,聽MSc; Edward W. J.听Rowe,聽MD; Richard J.听Bryant,聽FRCS(Urol), PhD; Jenny L.听Donovan,聽PhD; Penny聽Whiting,聽PhD
    Abstract Full Text
    open access
    榴莲视频 Netw Open. 2019; 2(8):e198427. 10.1001/jamanetworkopen.2019.8427

    This systematic review and meta-analysis investigates whether magnetic resonance imaging combined with targeted biopsy is associated with improved detection of clinically significant prostate cancer compared with transrectal ultrasonography鈥揼uided systematic prostate biopsy alone.

  • JAMA Original Investigation
    March 6, 2018

    Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial

    Richard M.听Martin,聽PhD; Jenny L.听Donovan,聽PhD; Emma L.听Turner,聽PhD; Chris聽Metcalfe,聽PhD; Grace J.听Young,聽MSc; Eleanor I.听Walsh,聽MSc; J. Athene聽Lane,聽PhD; Sian聽Noble,聽PhD; Steven E.听Oliver,聽PhD; Simon聽Evans,聽MD; Jonathan A. C.听Sterne,聽PhD; Peter聽Holding,聽MSc; Yoav聽Ben-Shlomo,聽PhD; Peter聽Brindle,聽MD; Naomi J.听Williams,聽PhD; Elizabeth M.听Hill,聽MSc; Siaw Yein聽Ng,聽PhD; Jessica聽Toole,聽MSc; Marta K.听Tazewell,聽MSc; Laura J.听Hughes,聽BA; Charlotte F.听Davies,聽PhD; Joanna C.听Thorn,聽PhD; Elizabeth聽Down,聽MSc; George聽Davey Smith,聽DSc; David E.听Neal,聽MD; Freddie C.听Hamdy,聽MD; CAP Trial Group
    Abstract Full Text
    free access
    JAMA. 2018; 319(9):883-895. 10.1001/jama.2018.0154

    This cluster randomized trial evaluates the effect of a single prostate-specific antigen (PSA) screening test on 10-year prostate cancer鈥搒pecific mortality among men aged 50 to 69 years treated at UK primary care practices.

  • JAMA Editorial
    March 21, 2017

    Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Helping Decision Making for Patients and Their Physicians

    Freddie C.听Hamdy,聽MD, FMedSci; Jenny L.听Donovan,聽PhD, FMedSci
    Abstract Full Text
    JAMA. 2017; 317(11):1121-1123. 10.1001/jama.2017.1703